Research ExplorerPublicationsAntiproliferative activity of bortezomib alone and in combin...

Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.

Standard

Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. / Wagenblast, Jens; Hambek, Markus; Baghi, Mehran; Gstöttner, Wolfgang; Strebhardt, Klaus; Ackermann, Hanns; Knecht, Rainald.

In: J CANCER RES CLIN, Vol. 134, No. 3, 3, 2008, p. 323-330.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wagenblast, J, Hambek, M, Baghi, M, Gstöttner, W, Strebhardt, K, Ackermann, H & Knecht, R 2008, 'Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.', J CANCER RES CLIN, vol. 134, no. 3, 3, pp. 323-330. <http://www.ncbi.nlm.nih.gov/pubmed/17701215?dopt=Citation>

APA

Wagenblast, J., Hambek, M., Baghi, M., Gstöttner, W., Strebhardt, K., Ackermann, H., & Knecht, R. (2008). Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J CANCER RES CLIN, 134(3), 323-330. [3]. http://www.ncbi.nlm.nih.gov/pubmed/17701215?dopt=Citation

Vancouver

Wagenblast J, Hambek M, Baghi M, Gstöttner W, Strebhardt K, Ackermann H et al. Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J CANCER RES CLIN. 2008;134(3):323-330. 3.

Bibtex

@article{ac21422d575f436bbdcda892b5bc466b,
title = "Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.",
abstract = "PURPOSE: Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, we investigated the antitumor effect of bortezomib (Velcade((R))) in squamous cell carcinoma of the head and neck (SCCHN) cell lines and examined the interaction of the drug with docetaxel (TAX) and cisplatin (CDDP). METHODS: Dose escalation studies were performed with eight squamous cell carcinoma cell lines using bortezomib alone or in combination with TAX or CDDP. Growth inhibitory and proapoptotic effects were measured quantitatively using cytohistology and western blot analysis. RESULTS: Bortezomib alone showed a significant antiproliferative activity in all SCCHN cell lines (P = 0.012), and the activity was further enhanced by the addition of TAX or CDDP (P",
author = "Jens Wagenblast and Markus Hambek and Mehran Baghi and Wolfgang Gst{\"o}ttner and Klaus Strebhardt and Hanns Ackermann and Rainald Knecht",
year = "2008",
language = "Deutsch",
volume = "134",
pages = "323--330",
journal = "J CANCER RES CLIN",
issn = "0171-5216",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.

AU - Wagenblast, Jens

AU - Hambek, Markus

AU - Baghi, Mehran

AU - Gstöttner, Wolfgang

AU - Strebhardt, Klaus

AU - Ackermann, Hanns

AU - Knecht, Rainald

PY - 2008

Y1 - 2008

N2 - PURPOSE: Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, we investigated the antitumor effect of bortezomib (Velcade((R))) in squamous cell carcinoma of the head and neck (SCCHN) cell lines and examined the interaction of the drug with docetaxel (TAX) and cisplatin (CDDP). METHODS: Dose escalation studies were performed with eight squamous cell carcinoma cell lines using bortezomib alone or in combination with TAX or CDDP. Growth inhibitory and proapoptotic effects were measured quantitatively using cytohistology and western blot analysis. RESULTS: Bortezomib alone showed a significant antiproliferative activity in all SCCHN cell lines (P = 0.012), and the activity was further enhanced by the addition of TAX or CDDP (P

AB - PURPOSE: Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, we investigated the antitumor effect of bortezomib (Velcade((R))) in squamous cell carcinoma of the head and neck (SCCHN) cell lines and examined the interaction of the drug with docetaxel (TAX) and cisplatin (CDDP). METHODS: Dose escalation studies were performed with eight squamous cell carcinoma cell lines using bortezomib alone or in combination with TAX or CDDP. Growth inhibitory and proapoptotic effects were measured quantitatively using cytohistology and western blot analysis. RESULTS: Bortezomib alone showed a significant antiproliferative activity in all SCCHN cell lines (P = 0.012), and the activity was further enhanced by the addition of TAX or CDDP (P

M3 - SCORING: Zeitschriftenaufsatz

VL - 134

SP - 323

EP - 330

JO - J CANCER RES CLIN

JF - J CANCER RES CLIN

SN - 0171-5216

IS - 3

M1 - 3

ER -